Award Data

DESCRIPTION (provided by applicant): In Phase I of this SBIR, ImmPORT Therapeutics and the UCI Proteomics Core developed a high throughput gene cloning and protein expression platform that allowed the proteomes of any sequenced infectious agent to be expre ssed and printed onto microarray chips. Since Phase I we have cloned and expressed ~15,000 genes from nearly 20 different pathogens associated ...

DESCRIPTION (provided by applicant): The primary focus of this Phase II proposal is development of a product against Alzheimer's disease (AD). AD is an increasingly important cause of morbidity and mortality in both hospital and long term nursing homes as well as in family environments. The direct and indirect cost of AD has been conservatively estimated at 149 billion in the U.S. Medicare expen ...

DESCRIPTION (provided by applicant): This research program will develop novel software and methods for monitoring distributed patterns of brain activation using real time functional magnetic resonance imaging (rtfMRI). This technology will be applied to the pain perception and regulation system with the ultimate goal of better understanding and controlling pain. These investigations further the NI ...

DESCRIPTION (provided by applicant): The Phase II work proposed here involves the high-throughput proteome profiling of molecules associated with cardiovascular disease. Comparative profiling of disease-relevant species will lead to a marketable product - the PPM Cardiovascular Health and Wellness Report. Molecular profiling is accomplished using novel IMS-MS instrumentation and a three-minute an ...

DESCRIPTION (provided by applicant): This amended trial (prior score 194) combines the experience and intellectual property of 3 NCI-funded Optical Breast Cancer groups, and proposes an early-detection cancer trial. With rare treatment exceptions (Tamoxifen, Herceptin), the long-term stage-specific mortality after breast cancer diagnosis has not appreciably changed in 50 years. In fact, the averag ...

DESCRIPTION (provided by applicant): Herpes simplex viruses infect humans worldwide. In the US, herpes simplex virus type 2 (HSV-2) infects about 17% of adults. Rates are far higher in the developing world, especially in populations with high HIV-1 prev alence. HSV-2 infections are permanent and the virus establishes latency in dorsal root ganglia neurons after infection. Periodic reactivatio ...

DESCRIPTION (provided by applicant): The primary objective of this project is to develop, using a novel vaccine platform technology (the VesiVax(r) system), a safe HSV2 vaccine that is capable of providing a level of protection in male and female human pop ulations which is better than other recombinant vaccines. We have shown that HSV2 VesiVax(r) vaccines targeted to single epitopes from the gD e ...

This application describes the development of real-time functional magnetic resonance imaging (rtfMRI) methods for use in treating addiction and craving in nicotine-dependent individuals. This Fast Track application falls under contract solicitation PHS2008-1#090, Develop a Real-time fMRI Feedback System that Allows Drug Abusers to Control their Cravings. Phase II: Perform a pilot cliical trial of ...

DESCRIPTION (provided by applicant): Project summary/Abstract Systemic lupus erythematosus (lupus) is an autoimmune disease that affects over a million people in the United States, disproportionately affecting women of childbearing age It is difficult to t reat and the few effective therapies have significant toxicities and side effects. The abnormal activation of two types of immune system cells, ...

DESCRIPTION (provided by applicant): Confidential information: Patent application in process. Diagnostics for the Real World, Ltd. (DRW) aims to market a high-performance duplex rapid test (DRW HIV-Ab/HBsAg Duplex Rapid Test), called DRW HIV-HBV Duplex, wh ich can simultaneously detect antibodies to HIV (HIV-Ab) for diagnosis of human immunodeficiency virus (HIV) infection and hepatitis B surface ...